HARUROPI (Accelagen Pty Ltd)
Product name
HARUROPI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
204 (255 working days)
Active ingredients
Ropinirole hydrochloride
Registration type
EOI
Indication
HARUROPI® is indicated as monotherapy, or in combination with levodopa, for the treatment of idiopathic Parkinson's disease from early stage to advanced disease.